McClellan to lead new Brookings group
This article was originally published in Pharmaceutical Approvals Monthly
Mark McClellan will stay at the Brookings Institution to lead a new health care group, the former CMS administrator and FDA commissioner says July 24. Among the health care challenges to be addressed by the Engelberg Center for Health Care Reform will be the creation of an active surveillance system for drug safety in the U.S. based on the standardization and coordination of independent data networks. McClellan, who has worked as visiting senior fellow at the Brookings/American Enterprise Institute Joint Center for Regulatory Studies since October, will be joined by former CMS Senior Adviser to the Administrator Larry Kocot, who will serve as a visiting fellow...
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.